Akili is in the process of building clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. Their aim is to develop a new type of Digital Medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians. Akili functions on the premise that advances in neuroscience research and consumer-facing technology are enabling a new way to sensitively measure neural function, and intervene in any measured deficits, wherever the patient may be. Akili's products address both quantitative measurement of and intensive intervention in cognitive functions in a variety of patient populations. Akili was co-founded by PureTech, leading cognitive neuroscientists, and top-tier entertainment software creators.


Latest News Entry
Akili is now listed on Nasdaq

Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022

Maker of the first-and-only FDA-cleared prescription video game treatment joins the ranks of Canva, Microsoft, SpaceX, and more

Akili to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

Akili Announces FDA Clearance of EndeavorRx™ for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game

Shown to improve attention function, EndeavorRx is backed by data from five clinical studies, including a prospective, randomized controlled trial

Akili Announces ENDEAVORTM Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA’s COVID-19 Enforcement Discretion Guidance

ENDEAVORTM (AKL-T01) is now available for use by children with attention deficit hyperactivity disorder (ADHD) and their families

Akili Completes $55 Million Financing to Advance Company’s Digital Medicine Platform and Product Pipeline Aimed at Treating Cognitive Dysfunction

Financing led by Temasek with new and existing investors including Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Funds, and Brooklands Capital Strategies

Proceeds will advance commercial and clinical-stage pipeline in ADHD, multiple sclerosis, and depression

Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Pivotal Trial

Company Completes Large Multi-Center, Randomized, Controlled Study of Novel Digital Medicine and Plans Regulatory Filing

Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million

BOSTON--(BUSINESS WIRE)-- Akili Interactive Labs, Inc. ("Akili"), a digital medicine company developing novel, non-pharmacological therapeutics and diagnostics for cognitive disorders, today announced an $11.9 million expansion of its recent Series B financing. *M Ventures, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States and Canada), and Amgen Ventures, the venture arm of Amgen, joined existing investors to bring the total Series B proceeds to $42.4 million. Akili will use the funds to support and expand clinical development of its clinical-stage products into new areas, with an expanded focus on neurodegeneration, and to build out its commercial infrastructure as Akili nears the market with its late-stage products. With the M Ventures and Amgen Ventures investments, Akili now has four relationships with major biopharma companies or their investment affiliates, including its existing partnership with Pfizer, Inc. and an investment from Shire Pharmaceuticals.

all related news
all portfolio news